AbbVie Stock Rises After FDA Approves 3rd Headache Drug

ABBV is up 23% year-over-year

Digital Content Manager
Sep 29, 2021 at 10:02 AM
facebook X logo linkedin

The U.S. Food and Drug Administration (FDA) just approved AbbVie Inc's (NYSE:ABBV) migraine prevention treatment, marking the company's third drug in its roster for severe headaches. The once-daily oral migraine medicine, known as Qulipta is one of the drugs acquired by ABBV in its $63 billion deal to buy Allergan that happened last year. 

ABBV was last seen up 0.6% at $107.95, though pressure still looms at the 20-day moving average. The stock has ben trading in a tight channel between its $108 an $106 levels since plummeting from its four-year high of $121.53 in mid-September. The stock has been testing support at its year-to-date breakeven level, though it sports a 23% year-over-year lead. 

Sentiment among analysts remains high, and of the 13 covering ABBV, just three say "hold," compared to 10 "buy" or better ratings. Plus, the 12-month consensus price target of $127.01 is a 17.5% premium to current levels. 

Options traders have also been optimistic. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 10-day call/put volume ratio of 3.59 stands higher than 86% of readings from the past year. This means long calls have rarely been more popular. 

Echoing this, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.39 is higher than just 4% of readings in its annual range, implying short-term options traders have been much more call-biased than usual. 


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI